ArticleMolecular diagnosis & therapy2020
Oncotype DX Breast Recurrence Score
Article in Molecular diagnosis & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 70 citations in OpenAlex.
- Current Therapies for Breast Cancer: What the Plastic Surgeon Needs to Know.Journal of clinical medicine · 2026Review
- Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.Cancer research communications · 2026Article
- Endothelial-derived PANoptosis factor IL33 is a potential immunotherapy in breast cancer.iScience · 2026Article
- ISG15-driven immune modulation and tumor progression in breast cancer metastasis: insights from single-cell and spatial transcriptomics.BMC medicine · 2026Article
- Case Report: Individualized circulating tumor DNA monitoring guides olaparib adjuvant therapy: an early-stage breast cancer case with somatic BRCA2 mutation.Frontiers in oncology · 2026Article
- Radiomics Analysis of QUS Spectral Parametric Images for Predicting the Risk of Breast Cancer Recurrence.Cancers · 2025Article
- Multimodal deep learning model for prediction of breast cancer recurrence risk and correlation with oncotype DX.Breast cancer research : BCR · 2025Article
- The OvarianTag™ Biomarker Panel Emerges as a Prognostic Tool to Guide Clinical Decisions in Cisplatin-Based Treatment of Epithelial Ovarian Cancer.International journal of molecular sciences · 2025Observational
- Cost-Effectiveness analysis of the 21-Gene platform for guiding treatment decisions for early Hormone-Positive breast cancer: the perspective of the Brazilian public health system.BMC health services research · 2025Article
- Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.Breast cancer research : BCR · 2025Article
- Review
- Machine learning-based diagnostic and prognostic models for breast cancer: a new frontier on the clinical application of natural killer cell-related gene signatures in precision medicine.Frontiers in immunology · 2025Article
- Correlation between histopathological features and recurrence score according to menopausal status in HR+/HER2- breast cancer patients: a retrospective study.Exploration of targeted anti-tumor therapy · 2025Article
- Digital profiling of gene expression from histology images with linearized attention.Nature communications · 2024Article
- How much do we know about the metastatic process?Clinical & experimental metastasis · 2024Review
- Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer.Gland surgery · 2024Article
- Anatomy Versus Biology: What Guides Chemotherapy Decisions in Older Patients With Breast Cancer?The Journal of surgical research · 2024Article
- Software BreastAnalyser for the semi-automatic analysis of breast cancer immunohistochemical images.Scientific reports · 2024Article
- Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.Geburtshilfe und Frauenheilkunde · 2024Article
- Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.Breast cancer research and treatment · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncotype DX Breast Recurrence Score
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.